Pharmacological approaches to smoking cessation

Stephen Israel Rennard, D. M. Daughton

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Cigarette smoking is a major cause of morbidity and mortality world-wide. Smoking cessation has immediate and long-term benefits and substantially reduces the risk of many smoking-related diseases. An increase in understanding of the addictive properties of nicotine has seen the development of several pharmacological approaches to smoking cessation. Nicotine replacement in the form of chewing gum, transdermal patches, inhalers or sprays approximately double the quit rate afforded by behavioural modification alone. These products are generally well tolerated. Therapy with other psychoactive drug may also aid smoking cessation. Bupropion is an inhibitor of the reuptake of noradrenaline and dopamine, and has been shown to improve smoking cessation rates. In one study, this drug was more effective than a nicotine patch and it has been approved for smoking cessation in the USA and Canada. Mecamylamine is a nicotine antagonist which blocks many of the physiological, behavioural and reinforcing effects of nicotine. In combination with transdermal nicotine, mecamylamine has been reported to significantly enhance quit rates. In summary, currently available pharmacological approaches to smoking cessation can help a number of patients to quit and should be considered as therapeutic options for those individuals who wish to do so.

Original languageEnglish (US)
Pages (from-to)334-338
Number of pages5
JournalEuropean Respiratory Review
Volume10
Issue number74
StatePublished - Jan 1 2000

Fingerprint

Smoking Cessation
Nicotine
Pharmacology
Mecamylamine
Smoking
Dopamine Uptake Inhibitors
Chewing Gum
Transdermal Patch
Tobacco Use Cessation Products
Bupropion
Nebulizers and Vaporizers
Psychotropic Drugs
Canada
Norepinephrine
Morbidity
Mortality
Therapeutics
Pharmaceutical Preparations

Keywords

  • Bupropion
  • Mecamylamine
  • Nicotine
  • Nicotine replacement therapy
  • Smoking cessation

ASJC Scopus subject areas

  • Medicine(all)
  • Pulmonary and Respiratory Medicine

Cite this

Rennard, S. I., & Daughton, D. M. (2000). Pharmacological approaches to smoking cessation. European Respiratory Review, 10(74), 334-338.

Pharmacological approaches to smoking cessation. / Rennard, Stephen Israel; Daughton, D. M.

In: European Respiratory Review, Vol. 10, No. 74, 01.01.2000, p. 334-338.

Research output: Contribution to journalArticle

Rennard, SI & Daughton, DM 2000, 'Pharmacological approaches to smoking cessation', European Respiratory Review, vol. 10, no. 74, pp. 334-338.
Rennard SI, Daughton DM. Pharmacological approaches to smoking cessation. European Respiratory Review. 2000 Jan 1;10(74):334-338.
Rennard, Stephen Israel ; Daughton, D. M. / Pharmacological approaches to smoking cessation. In: European Respiratory Review. 2000 ; Vol. 10, No. 74. pp. 334-338.
@article{b7ad176ec88c451eb166b68aeb8567bc,
title = "Pharmacological approaches to smoking cessation",
abstract = "Cigarette smoking is a major cause of morbidity and mortality world-wide. Smoking cessation has immediate and long-term benefits and substantially reduces the risk of many smoking-related diseases. An increase in understanding of the addictive properties of nicotine has seen the development of several pharmacological approaches to smoking cessation. Nicotine replacement in the form of chewing gum, transdermal patches, inhalers or sprays approximately double the quit rate afforded by behavioural modification alone. These products are generally well tolerated. Therapy with other psychoactive drug may also aid smoking cessation. Bupropion is an inhibitor of the reuptake of noradrenaline and dopamine, and has been shown to improve smoking cessation rates. In one study, this drug was more effective than a nicotine patch and it has been approved for smoking cessation in the USA and Canada. Mecamylamine is a nicotine antagonist which blocks many of the physiological, behavioural and reinforcing effects of nicotine. In combination with transdermal nicotine, mecamylamine has been reported to significantly enhance quit rates. In summary, currently available pharmacological approaches to smoking cessation can help a number of patients to quit and should be considered as therapeutic options for those individuals who wish to do so.",
keywords = "Bupropion, Mecamylamine, Nicotine, Nicotine replacement therapy, Smoking cessation",
author = "Rennard, {Stephen Israel} and Daughton, {D. M.}",
year = "2000",
month = "1",
day = "1",
language = "English (US)",
volume = "10",
pages = "334--338",
journal = "European Respiratory Review",
issn = "0905-9180",
publisher = "European Respiratory Society",
number = "74",

}

TY - JOUR

T1 - Pharmacological approaches to smoking cessation

AU - Rennard, Stephen Israel

AU - Daughton, D. M.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Cigarette smoking is a major cause of morbidity and mortality world-wide. Smoking cessation has immediate and long-term benefits and substantially reduces the risk of many smoking-related diseases. An increase in understanding of the addictive properties of nicotine has seen the development of several pharmacological approaches to smoking cessation. Nicotine replacement in the form of chewing gum, transdermal patches, inhalers or sprays approximately double the quit rate afforded by behavioural modification alone. These products are generally well tolerated. Therapy with other psychoactive drug may also aid smoking cessation. Bupropion is an inhibitor of the reuptake of noradrenaline and dopamine, and has been shown to improve smoking cessation rates. In one study, this drug was more effective than a nicotine patch and it has been approved for smoking cessation in the USA and Canada. Mecamylamine is a nicotine antagonist which blocks many of the physiological, behavioural and reinforcing effects of nicotine. In combination with transdermal nicotine, mecamylamine has been reported to significantly enhance quit rates. In summary, currently available pharmacological approaches to smoking cessation can help a number of patients to quit and should be considered as therapeutic options for those individuals who wish to do so.

AB - Cigarette smoking is a major cause of morbidity and mortality world-wide. Smoking cessation has immediate and long-term benefits and substantially reduces the risk of many smoking-related diseases. An increase in understanding of the addictive properties of nicotine has seen the development of several pharmacological approaches to smoking cessation. Nicotine replacement in the form of chewing gum, transdermal patches, inhalers or sprays approximately double the quit rate afforded by behavioural modification alone. These products are generally well tolerated. Therapy with other psychoactive drug may also aid smoking cessation. Bupropion is an inhibitor of the reuptake of noradrenaline and dopamine, and has been shown to improve smoking cessation rates. In one study, this drug was more effective than a nicotine patch and it has been approved for smoking cessation in the USA and Canada. Mecamylamine is a nicotine antagonist which blocks many of the physiological, behavioural and reinforcing effects of nicotine. In combination with transdermal nicotine, mecamylamine has been reported to significantly enhance quit rates. In summary, currently available pharmacological approaches to smoking cessation can help a number of patients to quit and should be considered as therapeutic options for those individuals who wish to do so.

KW - Bupropion

KW - Mecamylamine

KW - Nicotine

KW - Nicotine replacement therapy

KW - Smoking cessation

UR - http://www.scopus.com/inward/record.url?scp=0034070103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034070103&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 334

EP - 338

JO - European Respiratory Review

JF - European Respiratory Review

SN - 0905-9180

IS - 74

ER -